Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.

DI, Marks; P, Kebriaei; M, Stelljes; N, Gökbuget; H, Kantarjian; AS, Advani; A, Merchant; W, Stock; RD, Cassaday; T, Wang; H, Zhang; F, Loberiza; E, Vandendries; DJ, DeAngelo

doi:10.1016/j.bbmt.2019.04.020

Public

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.

Shared by NobleBlocks on Apr 27, 2019 • 12:00 AM UTC

Authors:

Marks DI

Kebriaei P

Stelljes M

Abstract

Attaining complete remission of acute lymphoblastic leukemia (ALL) before hematopoietic stem cell transplantation (HSCT) correlates with better post-transplant outcomes. Inotuzumab ozogamicin (InO), an anti-CD22 antibody conjugated to calicheamicin, has shown significantly higher rates of remission,...

Subject

Hematopoietic stem cell transplantation

Allogeneic transplantation

Inotuzumab Ozogamicin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!